$KNSA News
Last published 11h ago
- 11h agoKNSAKiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireLONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).
- 2w agoKNSAKiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsThank you for standing by and welcome to the Connexa Pharmaceuticals third quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a
- 2w agoKNSAKiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsThank you for standing by and welcome to the Connexa Pharmaceuticals third quarter 2026 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a
- 2w agoKNSAKiniksa Pharmaceuticals International, plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoKNSAKiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase
- 2w agoKNSAKiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026GlobeNewswireLONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern
- 2mo agoKNSAWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsGreat. So welcome to the next session of the Wells Fargo Healthcare Conference. My name is Eva Fortea. I'm one of the biotech analysts on the platform. And we have with us today, Ross Moat, COO and John Paolini, CMO of K
- 2mo agoKNSAWells Fargo 21st Annual Healthcare Conference - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsGreat. So welcome to the next session of the Wells Fargo Healthcare Conference. My name is Eva Fortea. I'm one of the biotech analysts on the platform. And we have with us today, Ross Moat, COO and John Paolini, CMO of K
- 2mo agoKNSAKiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireLONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare
- 3mo agoKNSACG 46th Annual Growth Conference - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsHi, good morning everyone. My name is Edward Nash, senior biotech analyst here at Canaccord Ingenuity and Equity Research. It is my pleasure to have with us today the management team from Connexia Pharmaceuticals. This i
- 3mo agoKNSACG 46TH ANNUAL GROWTH CONFERENCE - KINIKSA PHARMACEUTICALS INTERNATIONAL PLCEarnings Call TranscriptsHi, good morning everyone. My name is Edward Nash, senior biotech analyst here at Canaccord Ingenuity and Equity Research. It is my pleasure to have with us today the management team from Connexia Pharmaceuticals. This i
- 3mo agoKNSAKiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireLONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth
- 3mo agoKNSAKiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data
- 3mo agoKNSAKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026GlobeNewswireLONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern
- 5mo agoKNSAKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireLONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in June: 2026
- 6mo agoKNSAKiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2
- 6mo agoKNSAKiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026GlobeNewswireLONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern
- 7mo agoKNSAKiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent PericarditisGlobeNewswire– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on this
- 8mo agoKNSAApproval of Arcalyst, Bla #125249FDA Approved DrugsApproval Date: 03/10/2026; Drug Name: Arcalyst, Bla #125249; Active Ingredients: RILONACEPT; Company: Kiniksa Pharmaceuticals (uk), Ltd.; Submission Status: Approval; Application Number: 125249
- 8mo agoKNSAKiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswireLONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference
- 8mo agoKNSAKiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2
- 8mo agoKNSAKiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewswireLONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern
- 10mo agoKNSAKiniksa Pharmaceuticals Provides Corporate UpdateGlobeNewswire– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2
- 10mo agoKNSAKiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026
- 12mo agoKNSAKiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireLONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday,
- 1y agoKNSAKiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan
- 1y agoKNSAKiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025GlobeNewswireLONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern
- 1y agoKNSAKiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of PericarditisGlobeNewswireLONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need,
- 1y agoKNSAKiniksa Pharmaceuticals International, Plc (KNSA) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoKNSAKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireLONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in September:
- 1y agoKNSAKiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKNSAKiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3
- 1y agoKNSAKiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025GlobeNewswireLONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern
- 1y agoKNSAKiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent PericarditisGlobeNewswire– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and webcast at Jefferies 2025
- 1y agoKNSAKiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireLONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global
- 1y agoKNSAKiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent PericarditisGlobeNewswire– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that
- 1y agoKNSAKiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3
- 1y agoKNSAKiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025GlobeNewswireLONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern
- 1y agoKNSAKiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3
- 1y agoKNSAKiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate StrategyGlobeNewswire– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Kiniksa continues to focus
- 1y agoKNSAKiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025GlobeNewswireLONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern
- 1y agoKNSAKiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue GuidanceGlobeNewswire– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– Kiniksa expects to
- 1y agoKNSAKiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025
- 1y agoKNSAKiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireLONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx
- 1y agoKNSAKiniksa Pharmaceuticals to Present at Jefferies London Healthcare ConferenceGlobeNewswireLONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference
- 2y agoKNSAKiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoKNSAKiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionGlobeNewswire– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life DisRPted ™
- 2y agoKNSAKiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent PericarditisGlobeNewswire– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc
- 2y agoKNSAKiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024GlobeNewswireLONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern
- 2y agoKNSANHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent PericarditisGlobeNewswireLONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey League™ (NHL)